Accelerate Diagnostics Sees Prelim. Q4 Sales $3.3M vs $3.92M Est., FY21 Sales $11.8M vs $12.28M Est.

by Hal Lindon, Benzinga Editor
January 13, 2022 9:17 AM | 5 seconds read |

Accelerate Diagnostics Sees Prelim. Q4 Sales $3.3M vs $3.92M Est., FY21 Sales $11.8M vs $12.28M Est.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsGuidance
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved